Experimental Drug Halts Infant Adnan's Seizures, Offering New Hope
Infant Adnan, who suffered a seizure approximately every 13 minutes since birth, has become seizure-free following treatment with an experimental drug. The breakthrough occurred at King’s College Hospital London in Dubai, after the Dubai Health Authority (DHA) granted an application for the drug’s use through a "compassionate use" pathway. This pathway allows for medications not yet approved for commercial use to be administered in rare, critical cases. Adnan's story, reported by the Khaleej Times, highlights a significant step in personalized medicine for extremely rare genetic conditions.

The experimental oral medication, named ABS-1230, specifically targets abnormal activity in an ion channel linked to the extremely rare form of genetic epilepsy that Adnan suffers from. According to data from the treatment’s developer, Adnan is not only the youngest patient globally to receive ABS-1230 but also only the second infant to be administered this particular experimental drug. The medical team at the Dubai hospital was able to identify ABS-1230 as a potential treatment option after sequencing Adnan’s entire genome, which revealed a specific gene variant associated with his severe seizures.
Led by Professor Ubaid Shah, a consultant pediatric neurologist and epileptologist at the hospital, the drug was administered on September 14th. The results were immediate and profound: Adnan's seizures stopped completely. Such was the success that Adnan was discharged from the hospital just one week later, having experienced no seizures during his stay. At a follow-up appointment on October 11th, no clinical seizures were recorded, and as of November 2nd, the infant continues to be seizure-free. This remarkable progress has allowed Adnan to begin passing early development milestones, a crucial step in his growth previously hampered by his condition.
Professor Shah described the outcome as an "exceptional moment," underscoring the potential of precision medicine to identify genetic causes of diseases and target them with specific treatments. While the response to ABS-1230 has been overwhelmingly positive for Adnan, Professor Shah and his colleagues emphasize that the treatment remains experimental. Further research is required to assess whether these results are sustained and to confirm the drug's long-term safety before it can be approved for broader public use. Adnan's condition will continue to be monitored closely, offering valuable insights into this promising new therapy.
Why it matters: This case demonstrates the potential of precision medicine for rare genetic disorders.
Editor's note: The draft accurately synthesizes the provided source text, capturing the medical details, the experimental nature of the treatment, and the specific milestones mentioned.
AI-generated and fact-checked against the original report; claims the gate cannot verify are held back.